Loading organizations...
§ Private Profile · 12 Washington Street, Second Floor Natick, MA 01760
Clinical-stage biotech developing therapies for cardiopulmonary & fibrotic diseases, including PAH & PH-ILD, with lead candidate ROC-101.
AllRock Bio is a clinical-stage biotechnology company based in Cincinnati, Ohio, that develops novel therapies for rare cardiopulmonary and fibrotic diseases. The organization primarily focuses on treating severe patient conditions such as pulmonary arterial hypertension and pulmonary hypertension with interstitial lung disease using its lead drug candidate, ROC-101, an oral pan-ROCK inhibitor exclusively licensed from global pharmaceutical corporation Sanofi. To advance ROC-101 into the upcoming Phase 2a ROCSTAR clinical trial, the enterprise secured $50 million in Series A financing backed by prominent venture capital firms Versant Ventures and Westlake BioPartners. The scientific advisory board includes recognized industry experts such as Mardi Gomberg, Marius Hoeper, and Vallerie McLaughlin to guide the company's clinical strategy. AllRock Bio was established in April 2024 by co-founders Catherine Pearce and Justin Thompson before launching publicly in September 2025.
AllRock Bio has raised $50.0M across 1 funding round.
AllRock Bio has raised $50.0M in total across 1 funding round.
AllRock Bio has raised $50.0M across 1 funding round. Most recently, it raised $50.0M Series A in September 2025.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| Sep 1, 2025 | $50M Series A | Versant Ventures, Westlake Village BioPartners | — | Announced |
AllRock Bio has raised $50.0M in total across 1 funding round.
AllRock Bio's investors include Versant Ventures, Westlake Village BioPartners.
AllRock Bio is a clinical-stage biotechnology company developing novel therapies for cardiopulmonary and fibrotic diseases, primarily targeting pulmonary arterial hypertension (PAH) and pulmonary hypertension with interstitial lung disease (PH-ILD).[1][2][3][4] Its lead product, ROC-101, is an oral, first-in-class pan-ROCK inhibitor licensed from Sanofi, designed to address inflammatory, proliferative, and fibrotic pathways in these life-threatening conditions with limited treatment options.[2][4][5] The company serves patients with PAH (five-year survival ~57%) and ILD-PH (~38%), solving unmet needs beyond symptom relief by targeting disease drivers like vascular remodeling.[4][5] Launched in 2024 with a $50 million Series A co-led by Versant Ventures and Westlake BioPartners, AllRock shows strong early momentum, planning Phase 2a trials (ROCsTAR) in 2025 to test ROC-101 alongside standard therapies.[2][4][6]
AllRock Bio was founded in 2024 by a team of former CinCor Pharma executives, including co-founder and CEO Catherine Pearce, DHSc, MBA, who bring cardiovascular drug development expertise from CinCor's successful path to AstraZeneca's $1.3 billion acquisition in 2022 for its hypertension drug baxdrostat.[2][5][6] Chief Scientific Officer Bill Marshall and others identified ROC-101—originally from Kadmon (acquired by Sanofi in 2021)—after consulting key opinion leaders (KOLs) on the need for pan-ROCK inhibition targeting both ROCK1 and ROCK2.[2][4][5] The idea emerged from recognizing ROCK inhibitors' validation in glaucoma and their potential in PAH's fibrotic clogging of pulmonary arteries, leading to an exclusive license from Sanofi and a $50 million launch round backed by prior CinCor investors like David Allison of Westlake BioPartners.[2][4][6] Early traction includes Phase 1 safety data supporting Phase 2 advancement.[4]
AllRock rides the wave of precision therapies for rare cardiopulmonary diseases, where PAH and fibrotic lung conditions affect limited patients but demand innovation amid stagnant survival rates and few disease-modifying options.[4][5] Timing aligns with ROCK pathway validation—FDA-approved for glaucoma and in other pipelines—now expanding to lungs, fueled by big pharma licensing (e.g., Sanofi, AstraZeneca precedents).[2][5] Market forces favor it: biotech M&A appetite for validated assets, investor confidence from team history, and regulatory push for orphan drugs in high-mortality areas.[2][6] AllRock influences the ecosystem by accelerating pan-ROCK class development, potentially enabling combo regimens and inspiring fibrosis-focused biotechs.[1][4]
AllRock's near-term catalyst is the 2025 Phase 2a readout, which could validate ROC-101's transformative potential and draw partnerships or further funding, building on its $50 million war chest and pipeline expansion.[2][4][6] Rising focus on fibrosis modifiers and AI-driven trial design will shape its path, positioning it for Phase 3 or acquisition akin to CinCor. As a nimble player with battle-tested leadership, AllRock could redefine PAH treatment, delivering the efficient, patient-centric therapies it champions from day one.[1][3]